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Discovery of a novel kinase hinge binder fragment
by dynamic undocking
Moira Rachman, ab Dávid Bajusz, b Anasztázia Hetényi,c Andrea Scarpino, b
Balázs Merő,d Attila Egyed,b László Buday,d
Xavier Barril ae and György M. Keserű *b
One of the key motifs of type I kinase inhibitors is their interactions with the hinge region of ATP binding
sites. These interactions contribute significantly to the potency of the inhibitors; however, only a tiny
fraction of the available chemical space has been explored with kinase inhibitors reported in the last twenty
years. This paper describes a workflow utilizing docking with rDock and dynamic undocking (DUck) for the
virtual screening of fragment libraries in order to identify fragments that bind to the kinase hinge region.
We have identified 8-amino-2H-isoquinolin-1-one (MR1), a novel and potent hinge binding fragment,
which was experimentally tested on a diverse set of kinases, and is hereby suggested for future fragment
growing or merging efforts against various kinases, particularly MELK. Direct binding of MR1 to MELK was
confirmed by STD-NMR, and its binding to the ATP-pocket was confirmed by a new competitive binding
assay based on microscale thermophoresis.
Introduction
Protein kinases are a major class of drug targets, with over 30
marketed drugs and 250 drug candidates undergoing clinical
studies, mainly but not only in various oncology indications.1
The majority of kinase inhibitors target ATP binding sites
(type I), which contain a conserved hinge region. For this
reason, one of the main challenges in the development of
kinase inhibitors is obtaining selectivity. Another major
challenge is avoiding an already congested IP space, as the
diversity of hinge binder scaffolds used in type I kinase
inhibitors is relatively limited.2 Consequently, these
chemotypes have barely been sampled, which prompts the
thorough exploitation of their chemical space.3,4 For example,
it has been shown recently that only 1% of potential hinge
binders are present in known kinase inhibitors.5
Fragment-based drug discovery (FBDD) has already been
used in many kinase programs4 and has the potential to
identify novel fragment-sized hinge binders and specifically
“evolve” the fragment for the targeted kinase.6,7 In fact, the
first FBDD derived drug on the market, vemurafenib, targets
the oncogenic V600E mutant of the B-Raf kinase.8 Structure-
based virtual screening approaches have been used effectively
for both the identification of novel fragment-sized hinge
binders and their optimization. In one case study, Kolb and
colleagues screened 730 000 compounds and discovered two
ligands with different hinge binder moieties. The initial set
was first filtered by kinase hinge binding pharmacophore
restraints and the resulting 21 418 compounds were docked
to the ATP site.9 In another study, Urich and colleagues
extracted core fragments from 2.3M commercially available
compounds. The resulting unique fragments were filtered for
kinase hinge pharmacophores, and were subsequently
docked into a panel of protein kinases. This strategy
identified a number of hinge binder fragments with no
previously reported activity against the investigated kinases.10
In this work, we used a novel screening strategy to find
potent hinge binding fragments. Our dynamic undocking11
based approach identified MR1 (Fig. 1A) that has been
experimentally validated against five kinase targets (Table 1).
Future fragment growing or merging efforts toward these
targets could avoid a congested druggable chemical space
(e.g. for JAK2) and could provide a suitable chemical starting
point to unmet medical needs (e.g. for MELK). JAK2 belongs
to the non-receptor tyrosine kinase family, for which the
V617F mutation is known to be implicated in
myeloproliferative disorders.12,13 MST3 belongs to the Ste20
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Fig. 1 A) Summary of the virtual screening workflow. B) Predicted binding modes of MR1 in the JAK2 ATP pocket. Both binding modes utilize
tridentate H-bond interactions with the backbone carbonyl and amide groups of the hinge residues E930 and L932. C) Kinase inhibitory profile of
MR1 overlaid on the kinase phylogenetic tree28 (coloured blue to red, from most active to least active). The table summarizes the respective IC50
values in μM units, with the same colouring scheme (illustration reproduced courtesy of Cell Signaling Technology, Inc., www.cellsignal.com). D)
1H NMR spectrum of MR1 (a) and saturation transfer difference NMR spectrum of MR1 in the presence of MELK (b). E) In the competitive, MST-
based binding assay, titration of MELK with MR1 reveals concentration-dependent binding with a Ki value of 5.47 μM and confirms the ATP-pocket
as the location of binding.
RSC Medicinal Chemistry Research Article
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serine/threonine protein kinase family, which has been
shown to promote proliferation and tumorigenicity.14
Maternal embryonic leucine zipper kinase (MELK) is a serine/
threonine kinase belonging to the CAMK family, and was
initially found to be expressed in a wide range of early
embryonic cellular stages.
More recently, MELK has been identified to be present in
several human cancers and stem cell populations with a
unique spatial and temporal pattern, which suggests a
prominent role in cell cycle control, cell proliferation,
apoptosis, cell migration, cell renewal, embryogenesis,
oncogenesis, and cancer treatment resistance and
recurrence.16 ERK2 is part of the Ras/Raf/MEK/ERK pathway,
which is often overactivated in a very wide range of cancers,
while RSK2 is a downstream effector of this pathway and
phosphorylates substrates involved in transcription,
translation, cell cycle regulation, and cell survival.15
Results and discussion
Here, we present a novel and potent hinge binding fragment,
MR1 (Fig. 1A), that was discovered through virtual screening
(VS) of our in-house fragment library19 using kinase hinge
pharmacophore information in a hierarchical VS strategy
(Fig. 1A). Our initial screening has been performed on JAK2
as a prototypic protein kinase with a large number of type I
inhibitors. It is well known that the kinase hinge region
exhibits a pronounced H-bond pattern with ATP or ATP-site
competitors and that these interactions are imperative for
type I kinase inhibitors to bind. As such, a typical VS strategy
would incorporate such information by ensuring that the
retained ligands maintain these features through the use of
e.g. pharmacophoric restraints. Here, we employ an
additional filter that emphasizes the importance of the
defined H-bonds through dynamic undocking (DUck11),
which estimates the robustness of H-bonds. DUck is an
orthogonal method to approaches meant to predict binding
free energies. Instead, it assesses structural stability through
evaluation of the robustness of H-bonds. The VS strategy
consisted of docking with rDock20 using pharmacophoric
restraints to ensure that the features necessary for H-bonding
with the hinge were present, then using DUck to estimate the
resistance to rupture of these H-bonds. This strategy led to
the discovery of MR1, which was tested on five kinases from
the major branches of the kinase phylogenetic tree (Fig. 1C),
each with several relevant indications (Table 1). MST3 and
MELK, in particular, have only few known potent inhibitors.
MR1 was found to inhibit four of the target kinases with
IC50 values in the low to mid-micromolar range
(corresponding to ligand efficiencies between 0.54–0.59),21
which is in line with its small size and other hinge binders of
this complexity.7 ERK2 was the only kinase that was not
inhibited; one possible reason behind this is the higher ATP
concentration (100 μM) in the ERK2 inhibition assay, as
compared to the rest of the kinases (10–50 μM), resulting in
a stronger competition of ATP toward the binding site. The
assessment of the binding mode of MR1 was based on the
docking and DUck scores. Two plausible solutions were
generated (Fig. 1B), both of which adopt a tridentate
interaction with the hinge. This was verified also for MELK:
here, pose 2 is clearly preferred (WQB value of 7.7 kcal mol
−1, vs.
1.6 kcal mol−1 for pose 1). The ability of fragments to bind
simultaneously in multiple orientations has been reported in
numerous occasions, and can even be favourable from an
entropic perspective.22 Depending on how the fragment is then
elaborated, it freezes into one binding mode or the other,23,24
which will likely stay conserved during the elaboration
process25 (this also means that the mentioned entropic gain
will be lost, but ideally, this is compensated by a larger
favourable enthalpy decrease due to additional secondary
interactions between the protein and the elaborated ligand).
The tridentate interaction is not often observed within kinases
(a bidentate interaction being the most common), but – as
supported by the inhibition data – a third interaction allows for
high versatility.26 This can be constrained at the optimization
phase for introducing family-specific substituents. In fact, it is
not the hinge binder but rather its decoration that determines
kinase selectivity. Consequently, selective kinase inhibitors can
stem from an unselective fragment.7,27
In addition to identifying MR1, we have observed a
stepwise enrichment of known hinge binders along the
workflow: while the whole fragment library contained known
hinge binders in 14.4% of the compounds (90 out of 624), this
ratio was 64.7% for the virtual hits after the DUck calculations
(11 out of 17). This can be considered as a retrospective
validation of the presented virtual screening workflow.
Next, we aimed to confirm the direct and ATP-competitive
binding of MR1 experimentally. For this purpose, we have
selected MELK, as MR1 displayed the strongest inhibitory
activity against this kinase. Direct binding to MELK was
confirmed by an STD-NMR measurement (Fig. 1D), while the
binding site was validated with a competitive MST-based
(microscale thermophoresis) assay developed in our lab
(Fig. 1E).
Table 1 Summary of the kinase targets investigated in this study
Branch Kinase Uniprot ID Clinical indications
AGC RSK2 P51812 Oncogenesis and leukemia15
CAMK MELK Q14680 Oncogenesis and cancer treatment resistance16
CMGC ERK2 P28482 Cervical17 and colorectal18 cancer
STE MST3 Q9Y6E0 Breast cancer14
TK JAK2 O60674 Myeloproliferative neoplasms (MPNs)12,13
RSC Medicinal ChemistryResearch Article
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The assay is based on the displacement of a fluorescently
labelled type I reference ligand (see the Experimental section)
and it has additionally enabled us to quantify the
dissociation constant of MR1 from MELK as 5.47 μM. Its
high ligand efficiency (LE = 0.67) nominates MR1 as a viable
starting point for optimizing ATP-site kinase inhibitors.
Experimental
Virtual screening
The structures were prepared using MOE 2016,29 by
removing water and cofactors, capping the termini and
gaps, and for protonation with default settings. For the
virtual screening, the JAK2 PDB structure, 3E64 (chain A)
was used.30 For docking, the cavity was defined in the
prepared structure by the reference ligand method, using
the crystallized ligand as reference. The fragment library
consisted of 624 compounds and was prepared with
LigPrep,31 so that ligands above 300 Da would be ignored,
at most eight stereoisomers, six tautomers and eight ring
conformers would be generated and lastly, probable
ionization states within the pH range of six to eight would
be generated.
The prepared library was docked with pharmacophoric
restraints at the hinge region, namely, Glu930, O and
Leu932, N. The pharmacophore was defined as a 2 Ångström
radius around the mentioned receptor atoms. If the feature
did not adhere to the positional constraints, rDock would
assign a positive (unfavourable) pharmacophore restraint
score, for which the cutoff was set to 0.5. Furthermore, a
high-throughput VS (HTVS) protocol was implemented, which
consisted of three stages, for which at every stage the number
of docking runs increases, and the rDock “SCORE.INTER”
filter becomes stricter. The filter was adapted to scores
expected for fragment-sized molecules which resulted in 93
compounds in total. DUck was performed on this set of
compounds, pulling from Leu932, N (pulling from Glu930, O
did not result in any additional filtering). The first step for a
DUck simulation is the definition of the chunk (a part of the
protein structure) that represents the local environment
surrounding the residue interacting with the ligand. When
selecting residues for the chunk, the following guidelines
were considered: I) selecting as few residues as possible to
reduce computational time, II) residues were not selected if
they would block the ligand from exiting the pocket during
the simulations based on the directionality of the H-bond,
III) residues were not removed if this would lead to the
possibility of solvent entering the pocket from areas other
than where the ligand is exiting, and lastly IV) preserving the
local environment of the interacting atoms in the already
prepared structures. The sequence gaps created during the
process of selecting the chunk residues were capped. For
this, each section of residues was split into separate chains,
and the termini of each chain were acetylated or methylated.
Lastly, the chunk was checked for clashes possibly created
during the capping of the chains. The chunk included the
following residues: 853–859, 861–865, 879–882, 898, 902, 911,
912, 927, 929–941, 976, 978, 980–984 and 993–996. After
production of the chunk, DUck performs I) automatic ligand
parameterization in MOE, II) minimization, III) equilibration,
and IV) two SMD simulations (at two different temperatures,
300 K and 325 K), in which the distance between the
interacting atoms in the ligand and protein is increased from
2.5 to 5.0 Å, and V) if the WQB value (work necessary to break
the H-bond) in the previous step reaches a pre-defined
threshold, then the system is sampled by a short unbiased
MD simulation, after which the resulting new structures are
fed into steps IV) and V); the last two steps being repeated in
a finite number of cycles (replicas).11 Steps II) to V) were
performed with GPU-based pmemd.cuda in AMBER. Here, up
to five replicas of steps IV) and V) were performed, during
which a WQB threshold of 6 kcal mol
−1 (work necessary to
break the H-bond) was used, so that the simulations were
discontinued if the measured WQB in any replica was below
the threshold. If five runs were completed, the lowest
obtained WQB value was used, which resulted in 17
compounds that surpassed the threshold. Finally, we checked
the novelty of these fragments against known kinase
inhibitors by substructure searches, which ultimately led to
the selection of compound MR1 for experimental validation.
To suggest a binding pose for MELK, MR1 was docked in
all liganded MELK structures available. Both poses in Fig. 1B
were identified and submitted to a DUck simulation, pulling
from the NH atom in the hinge (Cys 89 N). Chunks were
derived by selecting residues within 10 Å from Cys89 N.
To check for known hinge binders in the fragment library,
all kinase inhibitors found in the ATP binding site were
downloaded from the KLIFS database.32 The cores (5
Angstrom from the hinge NH group) were extracted from
known binders from KLIFS and from the compounds in the
fragment library. A substructure search was performed to
find which of the fragment cores in the library were present
in the known hinge binder cores.
Kinase inhibition assay
MR1 (purity 97% by LC/MS) was tested against the target
kinases with the Z′-LYTE kinase inhibition assay (Life
Technologies). The assay employs a fluorescence-based
format and is based on the different sensitivities of
phosphorylated and nonphosphorylated peptides to
proteolytic cleavage. A suitable peptide substrate is labelled
with two fluorophores, forming a FRET pair. After incubating
the kinase + peptide + test compound mixture for an hour, a
development reaction is carried out. Any peptide that was not
phosphorylated by the kinase is cleaved, disrupting the
resonance energy transfer between the FRET pair. The
reaction progress is quantified based on the ratio of the
detected emission at 445 nm (coumarin) and 520 nm
(fluorescein), i.e. the ratio of cleaved vs. intact peptides. A
more detailed description of the assay is available on the
website of Life Technologies.33 IC50 values were determined
RSC Medicinal Chemistry Research Article
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from 10-pt titration measurements (with duplicate
datapoints) using the SelectScreen™ Biochemical Kinase
Profiling Service available at Life Technologies.
NMR measurements
The human MELK protein (Q14680) DNA was obtained from
OriGene and the kinase–uba domain (1–337) sequence was
cloned into a modified pET vector encoding an N-terminal
His-tag. The recombinant protein was expressed in E. coli
BL21 pLysS cells, harvested by centrifugation and purified by
immobilized metal affinity chromatography and anion
exchange chromatography. 1H and STD-NMR measurements
were performed using a 600 MHz Bruker Avance III
spectrometer equipped with a 5 mm cryo-TXI (1H, 13C, 15N)
probe with z-gradient at 298 K. The MELK protein and MR1
were dissolved in a 10% (v/v) D2O and H2O mixture
containing 20 mM Tris buffer (pH 8.0), 260 mM NaCl, 1 mM
TCEP and 5% glycerol. Spectra were acquired with water
suppression using excitation sculpting with the pulsed
gradient scheme. For the 1H and STD measurements, the
MELK and MR1 concentrations were 2.14 and 50 μM,
respectively. As a reference, STD experiments were also
performed without the target, containing the ligand species
alone.
STD-NMR spectra were acquired using a series of 40
equally spaced 50 ms Gaussian-shaped pulses for selective
saturation of the protein, with a total saturation time of 2 s
and a 50 ms spinlock to suppress protein signals. The
frequency of the on-resonance saturation was set at 1.0 ppm
and the off-resonance saturation frequency was set at 40.0
ppm. A total of 2000 scans were collected for each pseudo-2D
experiment.
Microscale thermophoresis binding assay
Microscale thermophoresis measurements were conducted
on a NanoTemper Monolith NT.115 device, using the red
fluorescence channel. MELK was stored and applied in a
buffer consisting of 20 mM Tris, 260 mM NaCl, 1 mM TCEP
and 5% glycerol, at a pH of 8.0. The MR1 stock was prepared
in DMSO and diluted into the protein buffer, with the final
DMSO concentrations not exceeding 1%. We have applied
the ligand displacement assay principle to detect the
thermophoresis of the fluorescently labeled MELK reference
ligand Kinase Tracer 236 (ThermoFisher, cat. no. PV5592) at
increasing concentrations of MR1. A titration curve was
acquired with serial 1 : 1 dilutions starting from 100 μM
ligand concentration (with 0.56 μM protein, 50 nM Kinase
Tracer 236, 60% LED power, 20% MST power), with 11
datapoints. Each datapoint was acquired in triplicate. The
primary result was a relative EC50 value of MR1 against MELK
(21.1 μM), which was converted to a Ki value of 5.47 μM,
using the following formula:
K i ¼ EC50T½ 50
Kd
þ P½ 0
Kd
þ 1
(1)
In formula (1), [P]0 is the protein concentration at 0%
binding, [T]50 is the concentration of free tracer at 50% and
Kd is the dissociation constant of the tracer and protein,
which was evaluated to be 208 nM under the assay conditions
in a direct binding measurement.
Conclusions
Here, we report the discovery of a novel hinge binder using
a new computational screening protocol based on dynamic
undocking. 8-Amino-2H-isoquinolin-1-one (MR1) was found
to inhibit kinases from four major branches of the kinase
phylogenetic tree, with low to mid-micromolar potencies
(translating to ligand efficiencies between 0.54–0.59). All of
these kinases are relevant clinical targets, mostly for
oncological indications. In particular, MST3 and MELK have
few known potent inhibitors, presenting the opportunity to
create novel chemical matter for these kinases with a less
congested IP space. In addition to its versatile inhibitory
profile, direct binding of MR1 to MELK was confirmed by
STD-NMR, and its binding to the ATP site was validated by
an MST-based (microscale thermophoresis) ligand
displacement assay developed as part of this work.
Together, these findings nominate MR1 as a viable fragment
starting point for a range of type I kinase inhibitor
programs.
Abbreviations
AGC PKA, PKG and PKC containing families
ATP Adenosine triphosphate
CAMK Ca2+/calmodulin-dependent protein kinases
CMGC CDK, MAPK, GSK3 and CLK containing families
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protein kinase 1 (MAPK1)
JAK2 Janus kinase 2
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protein kinase 24 (STK24)
NMR Nuclear magnetic resonance
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